Axa’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-14,584
Closed -$1.24M 78
2025
Q4
$1.24M Sell
14,584
-2,508
-15% -$206K 0.59% 36
2025
Q3
$1.33M Sell
17,092
-699,815
-98% -$54.7M 0.67% 35
2025
Q2
$56.1M Buy
716,907
+71,796
+11% +$5.35M 0.16% 132
2025
Q1
$46.8M Sell
645,111
-46,851
-7% -$3.35M 0.15% 136
2024
Q4
$51.2M Sell
691,962
-83,539
-11% -$5.85M 0.16% 132
2024
Q3
$51.2M Sell
775,501
-227,001
-23% -$16.5M 0.15% 141
2024
Q2
$92.6M Sell
1,002,502
-373,433
-27% -$33.1M 0.28% 74
2024
Q1
$131M Buy
1,375,935
+7,173
+0.5% +$603K 0.39% 54
2023
Q4
$104M Sell
1,368,762
-100,130
-7% -$6.97M 0.34% 66
2023
Q3
$102M Sell
1,468,892
-348,482
-19% -$28M 0.36% 65
2023
Q2
$171M Buy
1,817,374
+447,265
+33% +$38.9M 0.57% 30
2023
Q1
$113M Sell
1,370,109
-40,971
-3% -$3.22M 0.39% 58
2022
Q4
$105M Buy
1,411,080
+223,287
+19% +$17.2M 0.38% 54
2022
Q3
$98.1M Sell
1,187,793
-34,753
-3% -$3.34M 0.39% 56
2022
Q2
$116M Sell
1,222,546
-72,835
-6% -$7.54M 0.43% 50
2022
Q1
$152M Sell
1,295,381
-67,363
-5% -$7.56M 0.43% 40
2021
Q4
$177M Sell
1,362,744
-303,351
-18% -$35.4M 0.45% 37
2021
Q3
$189M Buy
1,666,095
+393,740
+31% +$44.9M 0.53% 28
2021
Q2
$132M Buy
1,272,355
+53,019
+4% +$5M 0.37% 58
2021
Q1
$102M Sell
1,219,336
-72,019
-6% -$6.09M 0.31% 73
2020
Q4
$118M Sell
1,291,355
-112,123
-8% -$9.3M 0.37% 59
2020
Q3
$112M Sell
1,403,478
-296,042
-17% -$23.1M 0.4% 50
2020
Q2
$117M Buy
1,699,520
+263,336
+18% +$18.7M 0.46% 43
2020
Q1
$90.3M Sell
1,436,184
-34,719
-2% -$2.5M 0.45% 49
2019
Q4
$114M Buy
1,470,903
+56,259
+4% +$4.39M 0.47% 38
2019
Q3
$104M Buy
1,414,644
+262,776
+23% +$18.5M 0.41% 49
2019
Q2
$70.9M Buy
1,151,868
+149,007
+15% +$9.01M 0.28% 94
2019
Q1
$64M Buy
1,002,861
+198,927
+25% +$11.4M 0.25% 112
2018
Q4
$41M Buy
803,934
+52,866
+7% +$2.67M 0.18% 150
2018
Q3
$43.6M Buy
751,068
+290,775
+63% +$14.2M 0.16% 171
2018
Q2
$22.3M Buy
460,293
+47,190
+11% +$2.2M 0.09% 269
2018
Q1
$19.2M Sell
413,103
-90,126
-18% -$3.91M 0.08% 298
2017
Q4
$18.9M Sell
503,229
-1,977
-0.4% -$72.6K 0.07% 309
2017
Q3
$18.4M Sell
505,206
-139,131
-22% -$5.31M 0.08% 290
2017
Q2
$25.4M Sell
644,337
-49,725
-7% -$1.81M 0.12% 224
2017
Q1
$21.8M Sell
694,062
-12,144
-2% -$380K 0.1% 253
2016
Q4
$22.1M Sell
706,206
-590,970
-46% -$19.1M 0.1% 237
2016
Q3
$52.1M Sell
1,297,176
-220,572
-15% -$8.31M 0.23% 132
2016
Q2
$50.5M Buy
1,517,748
+787,464
+108% +$26.9M 0.22% 131
2016
Q1
$21.5M Buy
730,284
+19,416
+3% +$536K 0.1% 251
2015
Q4
$18.7M Sell
710,868
-35,316
-5% -$917K 0.08% 258
2015
Q3
$17.7M Sell
746,184
-8,550
-1% -$206K 0.07% 265
2015
Q2
$17.9M Buy
754,734
+125,892
+20% +$2.84M 0.07% 271
2015
Q1
$14.9M Buy
628,842
+129,234
+26% +$2.9M 0.06% 314
2014
Q4
$10.6M Buy
499,608
+1,680
+0.3% +$33.8K 0.04% 377
2014
Q3
$8.48M Buy
497,928
+16,698
+3% +$264K 0.04% 410
2014
Q2
$6.88M Sell
481,230
-8,466
-2% -$115K 0.03% 479
2014
Q1
$6.05M Buy
489,696
+7,404
+2% +$85.4K 0.03% 486
2013
Q4
$5.29M Sell
482,292
-44,208
-8% -$498K 0.02% 511
2013
Q3
$6.11M Buy
526,500
+19,830
+4% +$232K 0.03% 481
2013
Q2
$5.67M Buy
+506,670
New +$6M 0.03% 463

Other funds holding EW

Axa's EW Position: Q1 2026 in Review

Axa sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 14,584 shares — an estimated $1.24M sold.

Axa first reported a position in EW in Q2 2013 and held it in 51 quarters. The position peaked at $189M in Q3 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Axa reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
  • Axa sold 14,584 Edwards Lifesciences shares in Q1 2026, an estimated $1.24M.
  • Axa first reported a position in Edwards Lifesciences in Q2 2013 and held it in 51 quarters.
  • Axa's Edwards Lifesciences position peaked at $189M in Q3 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Axa's 13F filing for Q1 2026, filed 15 May 2026.